The phase III trials, KEYNOTE‐789 and CheckMate‐722 trials, showed trends towards improved survival with ICIs and chemotherapy in patients with TKI‐resistant EGFR‐mutated NSCLC, but they lacked statistical significance.16, 17. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.